Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184904 | 0.92 | EPHX2 (0.61) | EPHX2FAAHDGAT1GCGRADRB2 | |
| SCHEMBL10184403 | 0.91 | DGAT1 (0.54) | EPHX2FAAHDGAT1L3MBTL1HRH3 | |
| SCHEMBL10185060 | 0.90 | ALDH1A1 (0.52) | MAPK14 | |
| SCHEMBL10186156 | 0.90 | NPC1 (0.52) | EPHX2FAAHDGAT1L3MBTL1GCGR | |
| SCHEMBL10185053 | 0.89 | MLYCD (0.49) | EPHX2FAAHDGAT1L3MBTL1HRH3 | |
| SCHEMBL10185045 | 0.89 | EPHX2 (0.61) | EPHX2FAAHGCGR | |
| SCHEMBL10185254 | 0.89 | MAPK14 (0.50) | EPHX2DGAT1MAPK14GCGR | |
| SCHEMBL10185096 | 0.89 | ACSL1 (0.43) | EPHX2TEAD1FAAHDGAT1MAPK14 | |
| SCHEMBL10185066 | 0.89 | EPHX2 (0.43) | EPHX2TEAD1FAAHDGAT1MAPK14 | |
| SCHEMBL10185123 | 0.89 | RHOC (0.49) | EPHX2FAAHDGAT1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | EPHX2 1718/4885TEAD1 2681/4885FAAH 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.